valproic acid has been researched along with 2019 Novel Coronavirus Disease in 17 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with platinum-resistant ovarian cancer (PROC) have limited therapeutic options and poor survival." | 3.11 | Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer. ( Barathi, D; Dahagama, S; Dubashi, B; Ganesan, P; Goenka, L; Kayal, S; Krishnamoorthy, N; Mathaiyan, J; Nakka, T; Thumaty, DB, 2022) |
| "Since the emergence of coronavirus disease 2019 (COVID-19), neurological symptoms, syndromes, and complications associated with this multi-organ viral infection have been reported and the various aspects of neurological involvement are increasingly uncovered." | 2.72 | Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. ( Aghavali, S; Babadi, M; Daraie, P; Emamikhah, M; Jalili, M; Mehrabani, M; Mohaghegh, F; Pouranian, M; Rohani, M; Zaribafian, M, 2021) |
| "Valproic acid (VPA) has shown beneficial effects in vitro against SARS-CoV-2 infection, but no study has analyzed its efficacy in the clinical setting." | 1.72 | Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. ( Artero, A; Asensi, V; Asensi-Díaz, E; Blanes, R; Collazos, J; Domingo, P; Dueñas-Gutiérrez, C; Fernández-Araujo, N; Lalueza, A; Lamas-Ferreiro, JL; Ramos-Rincón, JM; Raya-Cruz, M; Roy-Vallejo, E; Sanz-Cánovas, J; Vilchez-Rueda, H, 2022) |
| "BACKGROUND Considering the ongoing coronavirus disease 2019 (COVID-19) pandemic, sufficient information about common and serious adverse events is needed to rapidly distribute COVID-19 vaccines worldwide." | 1.72 | Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report. ( Kamiyama, T; Mizuno, T; Suzuki, A; Suzuki, M; Takahashi, R, 2022) |
| "Individuals with serious mental illness are at increased risk of severe COVID-19 infection." | 1.72 | Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System. ( Capichioni, G; Clelland, J; Finnerty, M; Goff, DC; Kammer, J; Leckman-Westin, E; Lindenmayer, JP; Nemani, K; Olfson, M; Silverman, DJ; Smith, TE; Williams, SZ, 2022) |
| "In the current coronavirus disease 2019 (COVID-19) pandemic, many pediatric neurologists have switched to telemedicine visits for nonemergent outpatient evaluations." | 1.62 | Diagnosing and managing childhood absence epilepsy by telemedicine. ( Dabrowski, AK; Kelley, SA; Kossoff, EH; Singhi, S; Stafstrom, CE; Sun, LR, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 17 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, DE | 1 |
| Jang, GM | 1 |
| Bouhaddou, M | 1 |
| Xu, J | 1 |
| Obernier, K | 1 |
| White, KM | 1 |
| O'Meara, MJ | 1 |
| Rezelj, VV | 1 |
| Guo, JZ | 1 |
| Swaney, DL | 1 |
| Tummino, TA | 1 |
| Hüttenhain, R | 1 |
| Kaake, RM | 1 |
| Richards, AL | 1 |
| Tutuncuoglu, B | 1 |
| Foussard, H | 1 |
| Batra, J | 1 |
| Haas, K | 1 |
| Modak, M | 1 |
| Kim, M | 1 |
| Haas, P | 1 |
| Polacco, BJ | 1 |
| Braberg, H | 1 |
| Fabius, JM | 1 |
| Eckhardt, M | 1 |
| Soucheray, M | 1 |
| Bennett, MJ | 1 |
| Cakir, M | 1 |
| McGregor, MJ | 1 |
| Li, Q | 1 |
| Meyer, B | 1 |
| Roesch, F | 1 |
| Vallet, T | 1 |
| Mac Kain, A | 1 |
| Miorin, L | 1 |
| Moreno, E | 1 |
| Naing, ZZC | 1 |
| Zhou, Y | 1 |
| Peng, S | 1 |
| Shi, Y | 1 |
| Zhang, Z | 1 |
| Shen, W | 1 |
| Kirby, IT | 1 |
| Melnyk, JE | 1 |
| Chorba, JS | 1 |
| Lou, K | 1 |
| Dai, SA | 1 |
| Barrio-Hernandez, I | 1 |
| Memon, D | 1 |
| Hernandez-Armenta, C | 1 |
| Lyu, J | 1 |
| Mathy, CJP | 1 |
| Perica, T | 1 |
| Pilla, KB | 1 |
| Ganesan, SJ | 1 |
| Saltzberg, DJ | 1 |
| Rakesh, R | 1 |
| Liu, X | 1 |
| Rosenthal, SB | 1 |
| Calviello, L | 1 |
| Venkataramanan, S | 1 |
| Liboy-Lugo, J | 1 |
| Lin, Y | 1 |
| Huang, XP | 1 |
| Liu, Y | 1 |
| Wankowicz, SA | 1 |
| Bohn, M | 1 |
| Safari, M | 1 |
| Ugur, FS | 1 |
| Koh, C | 1 |
| Savar, NS | 1 |
| Tran, QD | 1 |
| Shengjuler, D | 1 |
| Fletcher, SJ | 1 |
| O'Neal, MC | 1 |
| Cai, Y | 1 |
| Chang, JCJ | 1 |
| Broadhurst, DJ | 1 |
| Klippsten, S | 1 |
| Sharp, PP | 1 |
| Wenzell, NA | 1 |
| Kuzuoglu-Ozturk, D | 1 |
| Wang, HY | 1 |
| Trenker, R | 1 |
| Young, JM | 1 |
| Cavero, DA | 1 |
| Hiatt, J | 1 |
| Roth, TL | 1 |
| Rathore, U | 1 |
| Subramanian, A | 1 |
| Noack, J | 1 |
| Hubert, M | 1 |
| Stroud, RM | 1 |
| Frankel, AD | 1 |
| Rosenberg, OS | 1 |
| Verba, KA | 1 |
| Agard, DA | 1 |
| Ott, M | 1 |
| Emerman, M | 1 |
| Jura, N | 1 |
| von Zastrow, M | 1 |
| Verdin, E | 1 |
| Ashworth, A | 1 |
| Schwartz, O | 1 |
| d'Enfert, C | 1 |
| Mukherjee, S | 1 |
| Jacobson, M | 1 |
| Malik, HS | 1 |
| Fujimori, DG | 1 |
| Ideker, T | 1 |
| Craik, CS | 1 |
| Floor, SN | 1 |
| Fraser, JS | 1 |
| Gross, JD | 1 |
| Sali, A | 1 |
| Roth, BL | 1 |
| Ruggero, D | 1 |
| Taunton, J | 1 |
| Kortemme, T | 1 |
| Beltrao, P | 1 |
| Vignuzzi, M | 1 |
| García-Sastre, A | 1 |
| Shokat, KM | 1 |
| Shoichet, BK | 1 |
| Krogan, NJ | 1 |
| Saiz, ML | 1 |
| DeDiego, ML | 1 |
| López-García, D | 1 |
| Corte-Iglesias, V | 1 |
| Baragaño Raneros, A | 1 |
| Astola, I | 1 |
| Asensi, V | 2 |
| López-Larrea, C | 1 |
| Suarez-Alvarez, B | 1 |
| Collazos, J | 1 |
| Domingo, P | 1 |
| Fernández-Araujo, N | 1 |
| Asensi-Díaz, E | 1 |
| Vilchez-Rueda, H | 1 |
| Lalueza, A | 1 |
| Roy-Vallejo, E | 1 |
| Blanes, R | 1 |
| Raya-Cruz, M | 1 |
| Sanz-Cánovas, J | 1 |
| Artero, A | 1 |
| Ramos-Rincón, JM | 1 |
| Dueñas-Gutiérrez, C | 1 |
| Lamas-Ferreiro, JL | 1 |
| De Picker, LJ | 1 |
| Leboyer, M | 1 |
| Geddes, JR | 1 |
| Morrens, M | 1 |
| Harrison, PJ | 1 |
| Taquet, M | 1 |
| Mizuno, T | 1 |
| Takahashi, R | 1 |
| Kamiyama, T | 1 |
| Suzuki, A | 1 |
| Suzuki, M | 1 |
| Nemani, K | 1 |
| Williams, SZ | 1 |
| Olfson, M | 1 |
| Leckman-Westin, E | 1 |
| Finnerty, M | 1 |
| Kammer, J | 1 |
| Smith, TE | 1 |
| Silverman, DJ | 1 |
| Lindenmayer, JP | 1 |
| Capichioni, G | 1 |
| Clelland, J | 1 |
| Goff, DC | 1 |
| Nakka, T | 1 |
| Goenka, L | 1 |
| Dubashi, B | 1 |
| Kayal, S | 1 |
| Mathaiyan, J | 1 |
| Barathi, D | 1 |
| Krishnamoorthy, N | 1 |
| Thumaty, DB | 1 |
| Dahagama, S | 1 |
| Ganesan, P | 1 |
| Bouaziz, N | 1 |
| Ben Rejeb, H | 1 |
| Ateb, S | 1 |
| Fourati, T | 1 |
| Chammas, F | 1 |
| Baha, D | 1 |
| Rosetti, R | 1 |
| Kalalou, K | 1 |
| Saba, G | 1 |
| Benadhira, R | 1 |
| Januel, D | 1 |
| Unal, G | 1 |
| Turan, B | 1 |
| Balcioglu, YH | 1 |
| Hachim, MY | 1 |
| Al Heialy, S | 1 |
| Hachim, IY | 1 |
| Halwani, R | 1 |
| Senok, AC | 1 |
| Maghazachi, AA | 1 |
| Hamid, Q | 1 |
| Andrade, G | 1 |
| Simões do Couto, F | 1 |
| Câmara-Pestana, L | 1 |
| Fox, AW | 1 |
| Stafstrom, CE | 1 |
| Sun, LR | 1 |
| Kossoff, EH | 1 |
| Dabrowski, AK | 1 |
| Singhi, S | 1 |
| Kelley, SA | 1 |
| Emamikhah, M | 1 |
| Babadi, M | 1 |
| Mehrabani, M | 1 |
| Jalili, M | 1 |
| Pouranian, M | 1 |
| Daraie, P | 1 |
| Mohaghegh, F | 1 |
| Aghavali, S | 1 |
| Zaribafian, M | 1 |
| Rohani, M | 1 |
| Urrea-Mendoza, E | 1 |
| Okafor, K | 1 |
| Ravindran, S | 1 |
| Absher, J | 1 |
| Chaubal, V | 1 |
| Revilla, FJ | 1 |
| Pitt, B | 1 |
| Sutton, NR | 1 |
| Wang, Z | 1 |
| Goonewardena, SN | 1 |
| Holinstat, M | 1 |
| McCarthy, C | 1 |
| Sacco, J | 1 |
| Fedele, S | 1 |
| Ho, M | 1 |
| Porter, S | 1 |
| Liloglou, T | 1 |
| Greenhalf, B | 1 |
| Robinson, M | 1 |
| Young, B | 1 |
| Cicconi, S | 1 |
| Chauhan, S | 1 |
| Tesfaye, B | 1 |
| Jackson, R | 1 |
| Sherratt, F | 1 |
| Shaw, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883] | Phase 2 | 301 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
3 reviews available for valproic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic].
Topics: Antiviral Agents; Benzodiazepines; Betacoronavirus; Bipolar Disorder; Body Temperature Regulation; B | 2020 |
Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.
Topics: Adult; Anticonvulsants; Ataxia; Azithromycin; Clonazepam; Cough; COVID-19; COVID-19 Drug Treatment; | 2021 |
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Topics: Animals; Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Fibrinolyt | 2021 |
2 trials available for valproic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Communicable Disease Control; COVID-19; Cytotoxins; Etoposide; Female | 2022 |
SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol.
Topics: Clinical Trials, Phase II as Topic; COVID-19; Epigenesis, Genetic; Female; Humans; Randomized Contro | 2021 |
12 other studies available for valproic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Cells, Cultured; COVID-19; Enzyme Inhibitors; Epi | 2021 |
Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19.
Topics: Aged; Blood Cell Count; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Inflamma | 2022 |
Association between serum lithium level and incidence of COVID-19 infection.
Topics: Antimanic Agents; Bipolar Disorder; COVID-19; Humans; Incidence; Lithium; Lithium Compounds; Valproi | 2022 |
Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; BNT162 Vaccine; Bromocriptine; COVID-19; Dantrol | 2022 |
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System.
Topics: Adult; Antipsychotic Agents; Cohort Studies; COVID-19; COVID-19 Testing; Female; Hospitals, Psychiat | 2022 |
[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate].
Topics: Anticonvulsants; Antipsychotic Agents; Betacoronavirus; Clozapine; Coronavirus Infections; COVID-19; | 2020 |
Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.
Topics: Antimanic Agents; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Humans; Lithium; P | 2020 |
Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells.
Topics: 2',5'-Oligoadenylate Synthetase; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
The Pharmaceutical Year That Was, 2020.
Topics: Accreditation; Administration, Sublingual; Anticonvulsants; Communication; COVID-19; COVID-19 Drug T | 2020 |
Diagnosing and managing childhood absence epilepsy by telemedicine.
Topics: Anticonvulsants; Child; Child, Preschool; COVID-19; Disease Management; Electroencephalography; Epil | 2021 |
Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis.
Topics: Adult; Clonazepam; COVID-19; GABA Agents; Humans; Male; Methylprednisolone; Neuroprotective Agents; | 2021 |